NCT06733038
Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT06733038 |
| Title | FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients. (AtezoTRIBE2) |
| Acronym | AtezoTRIBE2 |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | Yes |
| Sponsors | Gruppo Oncologico del Nord-Ovest |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | ITA |
CKB BOOST